Every 10-Q that Intellia Therapeutics, Inc (NTLA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NTLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTLA filings page.
Intellia Therapeutics (NTLA) reported Q3 2025 results showing collaboration revenue of $13,782 and a net loss of $101,324. Operating expenses fell year over year as research and development declined to $94,747 from $123,380, while general and administrative was essentially flat at $30,512. Other income, net, was $10,153, driven primarily by interest income.
Liquidity remained sizable with cash and cash equivalents of $193,389 and marketable securities of $476,469 as of September 30, 2025. Year to date, the company raised $128,175 through at-the-market share sales and ended the quarter with 115,787,285 shares outstanding; 115,829,926 shares were outstanding as of October 31, 2025. Stockholders’ equity was $748,422.
Strategic updates included a January workforce reduction of about 27% with $6,500 in restructuring charges. The company amended and partially terminated facility leases, paying $34,000 in February and $30,000 in April 2025, with $14,000 due in January 2026, and recorded $40,500 of prepaid rent tied to a new Tech Square lease. Collaboration activity included a $1,800 milestone recognized under the Regeneron agreements, termination of the ReCode agreement in September 2025, and termination of the SparingVision collaboration in October 2025 with the return of 50% of its Series A2 shares.